Tags: Drug.

Semagacestat (LY450139) was a candidate drug for a causal therapy against Alzheimer’s disease. It was originally developed by Eli Lilly and Élan and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients but in August 2010 a disappointing interim analysis in which semagacestat performed worse than the placebo led to the trials being stopped.

Semagacestat_structure.svg
ATC prefix
none
CAS number
425386-60-3
FDA UNII code
3YN0602W4W
IUPAC name
(2S)-2-hydroxy-3-methyl-N-((1S)-1-methyl-2-[(1S)-3-methyl-2-oxo-2345-tetrahydro-1H-3-benzazepin-1-yl]amino-2-oxoethyl)butanamide
PubChem
9843750

Loading...

This page contains content from the copyrighted Wikipedia article "Semagacestat"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.